NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Studying Different Formulations of SR13668 in Healthy Volunteers
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00896207
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Natural History of Autoimmune Diabetes and Its Complications
- Conditions
- Diabetes Mellitus Type 1Diabetes Mellitus Type 2
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2020-10-08
- Target Recruit Count
- 356
- Registration Number
- NCT00896610
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Pure Erythroid Leukemia (M6b)Adult Acute Megakaryoblastic Leukemia (M7)
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00895934
- Locations
- 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
- Conditions
- BRCA1 Mutation CarrierBreast CarcinomaEstrogen Receptor NegativeHER2/Neu NegativeHereditary Breast and Ovarian Cancer SyndromeBasal-Like Breast CarcinomaProgesterone Receptor NegativeSolid NeoplasmBRCA2 Mutation CarrierOvarian Carcinoma
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 98
- Registration Number
- NCT00892736
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00890747
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaContiguous Stage II Adult Burkitt LymphomaContiguous Stage II Adult Diffuse Large Cell LymphomaContiguous Stage II Adult Diffuse Mixed Cell LymphomaContiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaContiguous Stage II Adult Immunoblastic Large Cell LymphomaContiguous Stage II Adult Lymphoblastic LymphomaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular Lymphoma
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00891072
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Selumetinib in Cancers With BRAF Mutations
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00888134
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
- Conditions
- Extensive Stage Small Cell Lung CarcinomaRecurrent Small Cell Lung Carcinoma
- Interventions
- Biological: CixutumumabOther: Laboratory Biomarker Analysis
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 168
- Registration Number
- NCT00887159
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸The Medical Center of Aurora, Aurora, Colorado, United States
A Lifestyle Change Program to Prevent Type 2 Diabetes
- Conditions
- Prediabetes
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2012-05-07
- Target Recruit Count
- 58
- Registration Number
- NCT00886340
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
- Conditions
- GlioblastomaSupratentorial GlioblastomaGliosarcoma
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyBiological: BevacizumabOther: PlaceboOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 637
- Registration Number
- NCT00884741
- Locations
- 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States